logo-loader

Silence Therapeutics strengthens the business with two key appointments

Published: 07:30 21 Jun 2018 BST

boardroom table
There will be a new face around the boardroom table

Silence Therapeutics PLC (LON:SLN) has made two key appointments that will respectively strengthen the board and the business. 

Dave Lemus, currently chief operating officer and chief financial officer of Proteros  Biostructures, has been appointed an independent director.  

READ: Silence Therapeutics on track to be a clinical stage company by year-end

Chairman Annalisa Jenkins said: "Dave has joined at a pivotal time for the company. His successful track record and proven leadership in building and managing high performance management teams will strengthen our capabilities as we continue to maximise the potential of our GalNAc-based SRNi platform."

Meanwhile, Richard Jenkins comes on board as head of clinical development, replacing chief scientific officer Torsten Hoffmann who is leaving Silence for personal reasons.

Jenkins, who has worked for Takeda and GlaxoSmithKline, will oversee the development of the company's main drug candidate, a compound for iron overload, as it progresses towards clinical trials. He will report directly to chairman Jenkins.

 

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

31 minutes ago